Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial

Article Oncology

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Doris K. Hansen et al.

Summary: A retrospective analysis showed that the safety and efficacy of standard-of-care ide-cel therapy in RRMM patients were similar to those seen in the phase II KarMMa trial, despite most patients not meeting the trial eligibility criteria.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Letter Oncology

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

Utkarsh Goel et al.

BLOOD CANCER JOURNAL (2023)

添加到收藏夹

Article Oncology

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas Martin et al.

Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesus San-Miguel et al.

Summary: In patients with lenalidomide-refractory multiple myeloma, Ciltacabtagene autoleucel (CAR-T cell therapy) showed a lower risk of disease progression or death compared to standard care, highlighting its effectiveness in this patient population.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodriguez-Otero et al.

Summary: In this international phase 3 trial, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, was found to significantly prolong progression-free survival and improve response compared to standard regimens in patients with relapsed and refractory multiple myeloma. The toxicity of ide-cel was consistent with previous reports.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Biophysics

Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis

Oren Pasvolsky et al.

Summary: The study examined the impact of maintenance therapy after salvage second autologous hematopoietic cell transplant in multiple myeloma. Results showed that maintenance therapy was associated with improved 5-year outcomes for patients and did not increase the incidence of second cancers.

BONE MARROW TRANSPLANTATION (2022)

添加到收藏夹

Article Hematology

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group

Henrik Gregersen et al.

Summary: The study demonstrated that maintenance therapy with carfilzomib and dexamethasone after salvage ASCT can prolong time to progression (TTP) by approximately 8 months, with generally manageable toxicity and well-tolerated adverse effects such as thrombocytopenia, anemia, hypertension, dyspnea, and bacterial infections.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios A. Dimopoulos et al.

Summary: Elotuzumab plus lenalidomide and dexamethasone did not significantly improve progression-free survival compared to lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who are ineligible for HSCT. Further research is needed to improve frontline treatments.

LANCET HAEMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody

Ajai Chari et al.

Summary: Talquetamab treatment exhibited common adverse events like cytokine release syndrome, skin-related events, and dysgeusia, which were primarily low-grade; however, the drug induced substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau et al.

Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Hartmut Goldschmidt et al.

Summary: The efficacy of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) has not been clearly defined in the era of continuous novel agent treatment, however, patients who received this treatment may have benefited.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma

Marc-Andrea Baertsch et al.

Summary: Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) following re-induction treatment with carfilzomib/lenalidomide/dexamethasone (KRd) led to deep remissions and prolonged progression-free survival (PFS) in patients with relapsed and/or refractory multiple myeloma (RRMM). Maintenance treatment post salvage HDCT/ASCT further enhanced PFS, making this a safe and effective strategy for RRMM patients.

CANCERS (2021)

添加到收藏夹

Article Oncology